Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174627 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
A Phase 3 study of Anemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,781
- Enrollment target
- 20
- Study locations
NCT02174627 is a Phase 3 study of Anemia that has completed, run by AstraZeneca. The registered enrollment target is 2,781 participants, above the 389-participant average among 72 other Anemia trials with a reported enrollment target (615% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02174627, a Phase 3 study of Anemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,781 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Roxadustat
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - El Centro
- Research Site - Escondido
- Research Site - Glendale
- Research Site - Long Beach
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Lynwood
- Research Site - National City
- Research Site - Northridge
- Research Site - Orange
- Research Site - Sacramento
- Research Site - Sacramento
- Research Site - San Diego
- Research Site - San Dimas
- Research Site - San Francisco
Alabama
- Research Site - Birmingham
- Research Site - Huntsville
Arizona
- Research Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,781 participants |
| Start Date | 2014-06-26 |
| Est. Completion | 2018-10-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174627
The ClinicalTrials.gov registry entry for NCT02174627 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,781 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 389-participant average among 72 other Anemia trials with a reported enrollment target (615% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02174627 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT02174627 about?
NCT02174627 is a clinical study titled "Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis". The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis
What is the current status of trial NCT02174627?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,781 participants. The study started on 2014-06-26. Estimated completion is 2018-10-04.
What conditions does trial NCT02174627 study?
This clinical trial studies the following conditions: Anemia.
What interventions are being tested in trial NCT02174627?
The interventions under investigation include: Placebo (DRUG), Roxadustat (DRUG).
Who is sponsoring clinical trial NCT02174627?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02174627 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.